

**MINUTES OF THE October 12th, 2010  
PHARMACY AND THERAPEUTICS (P&T) COMMITTEE MEETING**

**MEMBERS ATTENDING:** Hosan Azomani, M.D.; Joyce Brewer, Ph.D.; Sharon Dickey, Pharm.D.; Ryan Harper Pharm.D.; Lonnie Hicks, R.Ph.; Deborah Minor, Pharm.D.; John Mitchell M.D.; Carol Tingle, M.D.; Lee Voulters M.D.; Geri Lee Wieland M.D.; Wilma Wilbanks, R.Ph.

Also present: Judith Clark, R.Ph., Pharmacy Director, DOM; Terri Kirby, R.Ph., DOM; J. David Wuest, R.Ph., Provider Synergies

**MEMBERS ABSENT:** Billy Brown, Pharm.D.;

**CALL TO ORDER:** Dr. Minor called the meeting to order.

**INTRODUCTIONS:** Ms. Clark welcomed attendees to the meeting. She introduced new members, John Mitchell, M.D. and Geri Lee Wieland, M.D. She requested that everyone at the table introduce themselves. She thanked the Committee members for their work and introduced the DOM pharmacy staff and attendees from DOM's other pharmacy vendors, HID and ACS. ACS staff participated in the meeting via tele-conference.

**ADMINISTRATIVE MATTERS:** Ms. Clark outlined procedural and safety guidelines for the meeting. She noted that the P&T Committee is an advisory committee and that the DOM has the final say regarding the PDL. She stated that the PDL decisions for classes reviewed at this meeting will be post at the website by December 1, 2010, and will become effective on January 1, 2011. She announced the 2011 P&T schedule and provided copies of the schedule to the Committee members and the public. Ms. Clark provided updates on the new DUR process, a more user friendly 72 hour emergency medication override, plans to improve the State's electronic prior authorization program and EPDST access.

Leslie Leon, Pharm.D., Clinical Pharmacist, presented an overview of ACS's emergency 72 hour POS override program and implementation of a SMART PA process for pharmacy claims.

**DRUG CLASS ANNOUNCEMENTS:** Ms. Clark stated that DOM and Provider Synergies continually review drug classes for the PDL process based on the clinical and financial benefits. She informed the Committee that the Cough and Cold class will be reviewed at this meeting. She provided the Committee with an overview on the current policy regarding Cough and Cold agents. The Committee was instructed that there is no guarantee that DOM will alter their current policy regarding coverage of additional cough and cold preparations. However, the DOM is requesting the Committee's direction and recommendations. She thanked the Committee in advance for providing assistance in the class of medications.

**APPROVAL OF SEPTEMBER 14TH, 2010 MEETING MINUTES:** Dr. Minor asked for changes or a motion to approve the minutes from the September 14, 2010, P&T Committee meeting. Dr. Harper requested that typographical errors be fixed and he motioned that the minutes be approved. Mr. Hicks seconded the motion and the minutes were approved unanimously.

**PRESENTATIONS BY ADVOCACY GROUPS:** Elisa Smith, Registered Dietician spoke regarding Medicaid recipient access to nutritional products on behalf of The Mississippi Dietetics Association

**THERAPEUTIC CLASS REVIEWS:** Mr. Wuest stated that he will be presenting new information not previously covered in the Committee's reviews.

Michael W. Jann, Pharm.D. presented clinical information regarding Suboxone on behalf of Reckitt Benckiser.

**ACNE AGENTS, TOPICAL**

Mr. Wuest presented a brief overview of this class. Mr. Wuest presented the PDL recommendations for the class:

DRAFT

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
BENZOYL PEROXIDE OTC (TOPICAL)	ON	<b>Yes-Generic</b>
BENZOYL PEROXIDE (TOPICAL)	ON	<b>Yes-Generic</b>
RETIN-A MICRO (TOPICAL)	ON	<b>Yes</b>
AZELEX (TOPICAL)	ON	<b>Yes</b>
AKNE-MYCIN (TOPICAL)	OFF	<b>No</b>
ERYTHROMYCIN (TOPICAL)	ON	<b>Yes-Generic</b>
CLINDAMYCIN PHOSPHATE (TOPICAL)	ON	<b>Yes-Generic</b>
SULFACETAMIDE / SULFUR (TOPICAL)	ON	<b>Yes-Generic</b>
BPO/SULFUR (TOPICAL)	OFF	<b>No-Generic</b>
NUOX (TOPICAL)	ON	<b>Yes</b>
DIFFERIN (TOPICAL)	OFF	<b>No</b>
TAZORAC (TOPICAL)	OFF	<b>No</b>
ZACLIR (TOPICAL)	ON	<b>Yes</b>
BENZACLIN (TOPICAL)	ON	<b>Yes</b>
TRETINOIN (TOPICAL)	OFF	<b>No-Generic</b>
CLINAC BPO (TOPICAL)	ON	<b>Yes</b>
SE BPO (TOPICAL)	OFF	<b>No</b>
EVOCLIN (TOPICAL)	OFF	<b>No</b>
SULFACETAMIDE (TOPICAL)	OFF	<b>No-Generic</b>
ACANYA (TOPICAL)	OFF	<b>No</b>
INOVA (TOPICAL)	ON	<b>Yes</b>
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	OFF	<b>No-Generic</b>
ATRALIN (TOPICAL)	OFF	<b>No</b>
ACZONE (TOPICAL)	OFF	<b>No</b>
DUAC (TOPICAL)	OFF	<b>No</b>
CLARIFOAM EF (TOPICAL)	OFF	<b>No</b>
CLINDAMYCIN / BENZOYL PEROXIDE (TOPICAL)	OFF	<b>No-Generic</b>
BENZEFOAM (TOPICAL)	OFF	<b>No</b>
ZIANA (TOPICAL)	OFF	<b>No</b>
ADAPALENE GEL (TOPICAL)	OFF	<b>No-Generic</b>
EPIDUO (TOPICAL)	OFF	<b>No</b>
ADAPALENE CREAM (TOPICAL)	OFF	<b>No-Generic</b>

No public testimony on this class was provided.

Dr. Brewer made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Ms. Wilbanks. The motion passed unanimously.

**ANALGESICS, NARCOTICS LONG**

Mr. Wuest noted that Exalgo has entered the market since the last time the Committee reviewed this class. He provided an overview of the new agent and the class.

Mr. Wuest presented the PDL recommendations for the class.

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
METHADONE (ORAL)	ON	<b>Yes-Generic</b>
DURAGESIC MATRIX (TRANSDERM.)	OFF	<b>No</b>
KADIAN (ORAL)	ON	<b>Yes</b>
MORPHINE ER (ORAL)	ON	<b>Yes-Generic</b>
DURAGESIC (TRANSDERM.)	ON	<b>Yes</b>
ULTRAM ER (ORAL)	OFF	<b>No</b>
TRAMADOL ER (ORAL)	OFF	<b>No-Generic</b>
RYZOLT (ORAL)	OFF	<b>No</b>
OPANA ER (ORAL)	OFF	<b>No</b>
AVINZA (ORAL)	OFF	<b>No</b>
EMBEDA (ORAL)	OFF	<b>No</b>
FENTANYL (TRANSDERM)	ON	<b>Yes-Generic</b>
OXYCONTIN (ORAL)	OFF	<b>No</b>
EXALGO (ORAL)	OFF	<b>No</b>
OXYCODONE ER (ORAL)	OFF	<b>No-Generic</b>

No public testimony on this class was provided.

Dr. Azomani made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Dr. Brewer. The motion passed unanimously.

**ANALGESICS, NARCOTICS SHORT**

Mr. Wuest presented a brief overview of the class including an update of FDA advisory committee recommendation.

Mr. Wuest presented the following PDL recommendations for the class:

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
TRAMADOL (ORAL)	ON	<b>Yes-Generic</b>
PROPOXYPHENE / APAP (ORAL)	ON	<b>Yes-Generic</b>
APAP / CODEINE (ORAL)	ON	<b>Yes-Generic</b>
MEPERIDINE (ORAL)	ON	<b>Yes-Generic</b>
CODEINE (ORAL)	ON	<b>Yes-Generic</b>
HYDROCODONE / APAP (ORAL)	ON	<b>Yes-Generic</b>
PROPOXYPHENE (ORAL)	OFF	<b>No-Generic</b>
MORPHINE IR (ORAL)	ON	<b>Yes-Generic</b>
HYDROMORPHONE (ORAL)	ON	<b>Yes-Generic</b>
OXYCODONE / ASA (ORAL)	ON	<b>Yes-Generic</b>
DARVON-N (ORAL)	OFF	<b>No</b>
OXYCODONE / APAP (ORAL)	ON	<b>Yes-Generic</b>
OXYCODONE / IBUPROFEN (ORAL)	ON	<b>Yes-Generic</b>
REPREXAIN (ORAL)	OFF	<b>No</b>
HYDROCODONE / IBUPROFEN (ORAL)	ON	<b>Yes-Generic</b>
TRAMADOL / APAP (ORAL)	ON	<b>Yes-Generic</b>
PENTAZOCINE / APAP (ORAL)	ON	<b>Yes-Generic</b>
IBUDONE (ORAL)	ON	<b>Yes</b>
ZAMICET (ORAL)	OFF	<b>No</b>
DILAUDID LIQUID (ORAL)	OFF	<b>No</b>
OXYCODONE (ORAL)	ON	<b>Yes-Generic</b>
DIHYDROCODEINE / APAP / CAFFEINE (ORAL)	ON	<b>Yes-Generic</b>
BUTALBITAL COMPOUND W/CODEINE (ORAL)	OFF	<b>No-Generic</b>
PENTAZOCINE / NALOXONE (ORAL)	OFF	<b>No-Generic</b>
RYBIX ODT (ORAL)	OFF	<b>No</b>
HYCET (ORAL)	OFF	<b>No</b>
LEVORPHANOL (ORAL)	OFF	<b>No-Generic</b>
NUCYNTA (ORAL)	OFF	<b>No</b>
XODOL (ORAL)	OFF	<b>No</b>
OPANA (ORAL)	OFF	<b>No</b>
FENTORA (BUCCAL)	OFF	<b>No</b>
FENTANYL (BUCCAL)	OFF	<b>No-Generic</b>
ONSOLIS (BUCCAL)	OFF	<b>No</b>

No public testimony on this class was provided.

Dr. Dickey made a motion to accept the recommendations as presented. Dr. Harper seconded the motion, which passed unanimously.

### **ANALGESICS-ANESTHETICS, TOPICAL**

Mr. Wuest noted that Pennsaid has entered the market since the last time the Committee reviewed this class. He provided an overview of the new agent and the class.

Mr. Wuest presented the PDL recommendations for the class:

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
VOLTAREN (TOPICAL)	ON	<b>Yes</b>
PENNSAID (TOPICAL)	OFF	<b>No</b>
FLECTOR (TOPICAL)	ON	<b>Yes</b>
LIDODERM (TOPICAL)	ON	<b>Yes</b>

No public testimony on this class was provided. Tina Dancer, Pharm.D. yielded her time to the Committee on behalf of King.

Dr. Voulters made a motion to accept Provider Synergies' recommendations as presented. The motion was seconded by Dr. Azomani. The motion passed unanimously.

### **ANTIFUNGALS, TOPICAL**

Mr. Wuest presented a brief overview of the class including clinical information about the new agent in this class, Bensal HP.

Mr. Wuest then presented the PDL recommendations to the Committee:

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
NYSTATIN-TRIAMCINOLONE (TOPICAL)	ON	<b>Yes-Generic</b>
TERBINAFINE OTC (TOPICAL)	ON	<b>Yes-Generic</b>
NYSTATIN (TOPICAL)	ON	<b>Yes-Generic</b>
TOLNAFTATE OTC (TOPICAL)	ON	<b>Yes-Generic</b>
CLOTRIMAZOLE OTC (TOPICAL)	ON	<b>Yes-Generic</b>
MICONAZOLE OTC (TOPICAL)	ON	<b>Yes-Generic</b>
NAFTIN (TOPICAL)	ON	<b>Yes</b>
EXELDERM (TOPICAL)	OFF	<b>No</b>
KETOCONAZOLE (TOPICAL)	OFF	<b>No-Generic</b>
KETOCONAZOLE SHAMPOO (TOPICAL)	ON	<b>Yes-Generic</b>
CLOTRIMAZOLE RX (TOPICAL)	ON	<b>Yes-Generic</b>
OXISTAT (TOPICAL)	OFF	<b>No</b>
CLOTRIMAZOLE-BETAMETHASONE (TOPICAL)	ON	<b>Yes-Generic</b>
ECONAZOLE (TOPICAL)	ON	<b>Yes-Generic</b>
ERTACZO (TOPICAL)	OFF	<b>No</b>
VUSION (TOPICAL)	OFF	<b>No</b>
CICLOPIROX CR/SUSP/GEL (TOPICAL)	ON	<b>Yes-Generic</b>
LAMISIL SOLUTION (TOPICAL)	ON	<b>Yes</b>
XOLEGEL (TOPICAL)	OFF	<b>No</b>
MENTAX (TOPICAL)	OFF	<b>No</b>
CICLOPIROX SHAMPOO (TOPICAL)	OFF	<b>No-Generic</b>
BENSAL HP (TOPICAL)	OFF	<b>No</b>
CICLOPIROX SOLUTION (TOPICAL)	OFF	<b>No-Generic</b>
EXTINA (TOPICAL)	OFF	<b>No</b>
KETOCON + PLUS (TOPICAL)	OFF	<b>No</b>
CNL 8 (TOPICAL)	OFF	<b>No</b>

No public testimony on this class was provided.

Dr. Brewer made a motion to approve the recommendations as presented by Provider Synergies. The motion was seconded by Dr. Tingle and passed unanimously.

## ANTIHYPURICEMICS

Mr. Wuest noted that Colcrys has entered the market since the last time the Committee reviewed this class and it is expected that generic colchicine will leave the market by the end of the year. He provided an overview of the new agent and the class.

Mr. Wuest presented the PDL recommendations for this class:

Brand Name	Current PDL Status	PDL Recommendation
ALLOPURINOL (ORAL)	ON	Yes-Generic
COLCHICINE (ORAL)	ON	Yes-Generic
PROBENECID (ORAL)	ON	Yes-Generic
PROBENECID / COLCHICINE (ORAL)	ON	Yes-Generic
ULORIC (ORAL)	OFF	No
COLCRYS (ORAL)	OFF	No

Public testimony on this class was provided on Colcrys by Arleen Decicco, Pharm.D. on behalf of URL Pharma.

Dr. Azomani made the motion to approve the recommendations as presented by Provider Synergies with the understanding that one colchicine product should be preferred. The motion was seconded by Dr. Weiland and passed unanimously.

## ANTIMIGRAINE AGENTS

Mr. Wuest noted that this class has no new agents in it since the last time the Committee reviewed it. He provided an overview of the class.

Mr. Wuest presented the PDL recommendations:

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
MAXALT MLT (ORAL)	OFF	<b>No</b>
IMITREX (NASAL)	ON	<b>No</b>
IMITREX (SUBCUTANE.)	ON	<b>No</b>
RELPAK (ORAL)	ON	<b>Yes</b>
AXERT (ORAL)	OFF	<b>No</b>
FROVA (ORAL)	OFF	<b>No</b>
TREXIMET (ORAL)	ON	<b>Yes</b>
MAXALT / MLT (ORAL)	OFF	<b>No</b>
ZOMIG / ZOMIG ZMT (ORAL)	OFF	<b>No</b>
ZOMIG (NASAL)	OFF	<b>No</b>
CAMBIA (ORAL)	OFF	<b>No</b>
SUMATRIPTAN (ORAL)	ON	<b>Yes-Generic</b>
IMITREX (ORAL)	ON	<b>No</b>
NARATRIPTAN (ORAL)	OFF	<b>No-Generic</b>
SUMATRIPTAN (NASAL)	ON	<b>Yes-Generic</b>
SUMATRIPTAN (SUBCUTANE.)	ON	<b>Yes-Generic</b>

Public testimony on this class was provided on Treximet by Vivian Tucker, Pharm.D. on behalf of GSK.

Dr. Voulters made a motion to accept the recommendations as presented. The motion was seconded by Dr. Brewer. The motion passed unanimously.

#### **ANTIPARASITICS, TOPICAL**

Mr. Wuest presented an overview of the class which is a new class to the Committee.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
PERMETHRIN OTC (TOPICAL)	ON	Yes-Generic
PERMETHRIN (TOPICAL)	ON	Yes-Generic
EURAX (TOPICAL)	ON	Yes
ULESFIA (TOPICAL)	OFF	No
LINDANE (TOPICAL)	OFF	No-Generic
MALATHION (TOPICAL)	ON	Yes-Generic
OVIDE (TOPICAL)	OFF	No

Public testimony on this class was provided on Ulesfia by Kenneth Jackson on behalf of Shionogi and on Malathion and Ovide by David Benningfield on behalf of Taro Pharma.

Dr. Azomani made a motion to accept the recommendations as presented. The motion was seconded by Dr. Weiland and passed unanimously.

#### **ANTIVIRALS, TOPICAL**

No clinical information was presented on this class.

No public testimony on this class was provided.

Dr. Azomani made a motion to review this class at the next meeting. The motion was seconded by Dr. Weiland and passed unanimously

#### **CYTOKINE AND CAM ANTAGONISTS**

Mr. Wuest presented overview of this therapeutic class.

Mr. Wuest presented multiple PDL recommendations for the class. The Committee decided to utilize the following recommendation:

Brand Name	Current PDL Status	PDL Recommendation
ENBREL (INJECTION)	ON	Yes
HUMIRA (INJECTION)	ON	Yes
CIMZIA (INJECTION)	ON	No
ORENCIA (INJECTION)	OFF	No
ACTEMRA (INJECTION)	OFF	No
KINERET (INJECTION)	ON	Yes
SIMPONI (INJECTION)	OFF	No
AMEVIVE (INJECTION)	OFF	No
STELARA (INJECTION)	OFF	No
REMICADE (INJECTION)	OFF	No

Public testimony on this class was provided on Stelara and Simponi by Megan Jones, Pharm.D. on behalf of Johnson & Johnson and on Cimzia by Jay Vollett, M.D. on behalf of UCB. Pam Sardo, Pharm.D. yielded her time to the Committee on behalf of Abbott and Sanjay Mehta, Pharm.D. yielded his time to the Committee on behalf of Amgen.

Dr. Azomani made a motion to accept the recommendations as presented. The motion was seconded by Dr. Harper and passed unanimously.

#### **FIBROMYALGIA**

Mr. Wuest presented a brief overview of the class which is a new class to the committee.

Brand Name	Current PDL Status	PDL Recommendation
SAVELLA (ORAL)	ON	Yes
LYRICA (ORAL)	ON	Yes
CYMBALTA (ORAL)	OFF	No

Public testimony on this class was provided on Cymbalta by Esther Liu, Pharm.D. on behalf of Lilly. Arlene Cerbone yielded her time to the Committee on behalf of Forrest and Lee Ann Griffin, Pharm.D. yielded his time to the Committee on behalf of Pfizer.

Dr. Harper made a motion to accept the recommendations as presented. The motion was seconded by Dr. Azomani and passed by 10 to 1 vote. Ms. Wilbanks was opposed.

## **IMMUNOMODULATORS, ATOPIC DERMATITIS**

Mr. Wuest presented an overview of the class. There are no new agents in this class since the last time the Committee review the class.

Mr. Wuest made the following recommendations to the Committee:

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
PROTOPIC (TOPICAL)	ON	<b>Yes</b>
ELIDEL (TOPICAL)	ON	<b>Yes</b>

No public testimony on this class was provided. Marilyn Ripoll yielded her time to the Committee on behalf of Astellas.

Dr. Dickey made a motion to accept the recommendations as presented. The motion was seconded by Mr. Hicks and passed unanimously by the Committee.

## **NSAIDS**

Mr. Wuest noted that Vimovo has entered the market since the last time the Committee reviewed this class. He provided an overview of the new agent and the class.

Mr. Wuest made the following recommendations to the Committee:

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
PIROXICAM (ORAL)	ON	<b>Yes-Generic</b>
IBUPROFEN RX (ORAL)	ON	<b>Yes-Generic</b>
MELOXICAM (ORAL)	ON	<b>Yes-Generic</b>
KETOPROFEN (ORAL)	ON	<b>Yes-Generic</b>
FLURBIPROFEN (ORAL)	ON	<b>Yes-Generic</b>
KETOROLAC (ORAL)	ON	<b>Yes-Generic</b>
NAPROXEN (ORAL)	ON	<b>Yes-Generic</b>
INDOCIN SUSPENSION (ORAL)	OFF	<b>No</b>
SULINDAC (ORAL)	ON	<b>Yes-Generic</b>
DICLOFENAC (ORAL)	ON	<b>Yes-Generic</b>
ETODOLAC (ORAL)	ON	<b>Yes-Generic</b>
INDOMETHACIN (ORAL/RECTAL)	ON	<b>Yes-Generic</b>
FENOPROFEN (ORAL)	ON	<b>Yes-Generic</b>
OXAPROZIN (ORAL)	ON	<b>Yes-Generic</b>
ARTHROTEC (ORAL)	OFF	<b>No</b>
NABUMETONE (ORAL)	OFF	<b>No-Generic</b>
CELEBREX (ORAL)	OFF	<b>No</b>
VIMOVO (ORAL)	OFF	<b>No</b>
TOLMETIN (ORAL)	OFF	<b>No-Generic</b>
MECLOFENAMATE (ORAL)	OFF	<b>No-Generic</b>
ZIPSOR (ORAL)	OFF	<b>No</b>
INDOCIN (RECTAL)	OFF	<b>No</b>

Public testimony on this class was provided on Vimovo by Kim Lonergan on behalf of Astra Zeneca and on Celebrex by Lee Ann Griffin, Pharm.D. on behalf of Pfizer.

Dr. Azomani made a motion to approve the PDL as recommended. The motion was seconded by Ms. Wilbanks and was passed unanimously.

### **NUTRITIONALS, CALORIC AGENTS**

Mr. Wuest presented clinical data on agents in this class. He also provided an overview on how this class has been compared by the call center at the request of providers.

Mr. Wuest made the following recommendations to the Committee:

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
POLYCOSE (ORAL)	ON	<b>Yes</b>
DUOCAL (ORAL)	ON	<b>Yes</b>
PROMOD (ORAL)	ON	<b>Yes</b>
RESOURCE (ORAL)	ON	<b>Yes</b>
SCANDISHAKE (ORAL)	NR	<b>Yes</b>
JUVEN (ORAL)	ON	<b>Yes</b>
NUTRITIONAL SUPPLEMENT (ORAL)	NR	<b>Yes-Generic</b>
BRIGHT BEGINNINGS (ORAL)	ON	<b>Yes</b>
BOOST (ORAL)	ON	<b>Yes</b>
ENSURE (ORAL)	ON	<b>Yes</b>
CARNATION INSTANT BREAKFAST (ORAL)	ON	<b>Yes</b>
TWOCAL HN (ORAL)	ON	<b>Yes</b>
NUTREN (ORAL)	ON	<b>Yes</b>
OSMOLITE (ORAL)	ON	<b>Yes</b>
PEDIASURE (ORAL)	ON	<b>Yes</b>
FIBERSOURCE (ORAL)	OFF	<b>No</b>
ISOSOURCE (ORAL)	OFF	<b>No</b>
JEVITY (ORAL)	OFF	<b>No</b>
PROMOTE (ORAL)	OFF	<b>No</b>
EO28 SPLASH (ORAL)	OFF	<b>No</b>
COMPLEAT (ORAL)	OFF	<b>No</b>
VITAL (ORAL)	OFF	<b>No</b>
VIVONEX (ORAL)	NR	<b>No</b>
TOLEREX (ORAL)	OFF	<b>No</b>
PEPTAMEN (ORAL)	NR	<b>No</b>

Public testimony on this class was provided by Pam Roberts, R.D. on behalf of Ross Labs.

Dr. Harper made a motion to accept the recommendations as presented. Dr. Dickey seconded the motion, which passed unanimously.

### **SKELETAL MUSCLE RELAXANTS**

Mr. Wuest presented an overview of this class.

He presented the following recommendations to the Committee:

<b>Brand Name</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>
CARISOPRODOL (ORAL)	OFF	<b>No-Generic</b>
CHLORZOXAZONE (ORAL)	ON	<b>Yes-Generic</b>
CYCLOBENZAPRINE (ORAL)	ON	<b>Yes-Generic</b>
BACLOFEN (ORAL)	ON	<b>Yes-Generic</b>
CARISOPRODOL COMPOUND (ORAL)	OFF	<b>No-Generic</b>
METHOCARBAMOL (ORAL)	ON	<b>Yes-Generic</b>
TIZANIDINE (ORAL)	ON	<b>Yes-Generic</b>
ORPHENADRINE (ORAL)	OFF	<b>No-Generic</b>
AMRIX (ORAL)	OFF	<b>No</b>
ORPHENADRINE COMPOUND (ORAL)	OFF	<b>No-Generic</b>
DANTROLENE SODIUM (ORAL)	ON	<b>Yes-Generic</b>
SKELAXIN (ORAL)	OFF	<b>No</b>
SOMA 250 MG (ORAL)	OFF	<b>No</b>
ZANAFLEX CAPSULES (ORAL)	OFF	<b>No</b>
FEXMID (ORAL)	OFF	<b>No</b>
METAXALONE (ORAL)	OFF	<b>No-Generic</b>

No public testimony on this class was provided.

Dr. Dickey made a motion to accept the recommendations as presented. Dr. Voulters seconded the motion, which passed unanimously.

### **STEROIDS, TOPICAL HIGH**

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
TRIAMCINOLONE ACETONIDE (TOPICAL)	ON	Yes-Generic
BETAMETHASONE VALERATE (TOPICAL)	ON	Yes-Generic
FLUOCINONIDE EMOLLIENT (TOPICAL)	ON	Yes-Generic
FLUOCINONIDE-E (TOPICAL)	ON	Yes-Generic
FLUOCINONIDE (TOPICAL)	ON	Yes-Generic
BETAMETHASONE DIPROPIONATE (TOPICAL)	OFF	No-Generic
KENALOG AEROSOL (TOPICAL)	OFF	No
AMCINONIDE (TOPICAL)	OFF	No-Generic
HALOG (TOPICAL)	OFF	No
DIFLORASONE DIACETATE (TOPICAL)	OFF	No-Generic
VANOS (TOPICAL)	OFF	No
DESOXIMETASONE (TOPICAL)	OFF	No-Generic

No public testimony on this class was provided.

Dr. Tingle made a motion to approve the recommendations. The motion was seconded by Dr. Voulters. The motion was approved unanimously.

#### **STEROIDS, TOPICAL LOW**

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
HYDROCORTISONE OTC (TOPICAL)	ON	<b>Yes-Generic</b>
HYDROCORTISONE (TOPICAL)	ON	<b>Yes-Generic</b>
CAPEX SHAMPOO (TOPICAL)	ON	<b>Yes</b>
DESONIDE (TOPICAL)	ON	<b>Yes-Generic</b>
DERMA-SMOOTHIE-FS (TOPICAL)	OFF	<b>No</b>
ALCLOMETASONE DIPROPIONATE (TOPICAL)	OFF	<b>No-Generic</b>
DESONATE (TOPICAL)	OFF	<b>No</b>
PEDIADERM HC (TOPICAL)	OFF	<b>No</b>
VERDESO (TOPICAL)	OFF	<b>No</b>
DESONIL + PLUS (TOPICAL)	OFF	<b>No</b>

Public testimony on this class was provided on Derma-Smoothe-FS by Jerry Wells, R.Ph. on behalf of Hill Dermaceuticals.

Dr. Dingle made a motion to approve the recommendations. The motion was seconded by Ms. Wilbanks. The motion was approved unanimously.

### **STEROIDS, TOPICAL MEDIUM**

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented multiple PDL recommendations for the class. The Committee decided to utilize the following recommendation:

Brand Name	Current PDL Status	PDL Recommendation
PANDEL (TOPICAL)	NR	Yes
CLODERM (TOPICAL)	OFF	No
FLUOCINOLONE ACETONIDE (TOPICAL)	ON	Yes-Generic
HYDROCORTISONE VALERATE (TOPICAL)	ON	Yes-Generic
MOMETASONE FUROATE (TOPICAL)	ON	Yes-Generic
HYDROCORTISONE BUTYRATE (TOPICAL)	ON	Yes-Generic
LUXIQ (TOPICAL)	ON	Yes
FLUTICASONE PROPIONATE (TOPICAL)	ON	No-Generic
PREDNICARBATE (TOPICAL)	ON	Yes-Generic
CORDRAN TAPE (TOPICAL)	OFF	No
CUTIVATE LOTION (TOPICAL)	OFF	No
MOMEXIN (TOPICAL)	ON	No
LOCOID LIPOCREAM (TOPICAL)	NR	No

No public testimony on this class was provided.

Dr. Voulters made a motion to approve the recommendations. The motion was seconded by Dr. Azomani. The motion was approved unanimously.

#### **STEROIDS, TOPICAL VERY HIGH**

Mr. Wuest stated that there is no significant new clinical information to present for this class, but he did provide an overview of the class.

Mr. Wuest presented the PDL recommendations to the Committee:

Brand Name	Current PDL Status	PDL Recommendation
CLOBETASOL EMOLLIENT (TOPICAL)	ON	Yes-Generic
HALOBETASOL PROPIONATE (TOPICAL)	ON	Yes-Generic
CLOBETASOL PROPIONATE (TOPICAL)	ON	Yes-Generic
CLOBEX (TOPICAL)	OFF	No
HALONATE PAC (TOPICAL)	OFF	No-Generic
HALONATE (TOPICAL)	OFF	No-Generic
OLUX-E (TOPICAL)	OFF	No
OLUX-OLUX-E (TOPICAL)	OFF	No

No public testimony on this class was provided.

Dr. Tingle made a motion to approve the recommendations. The motion was seconded by Dr. Voulters. The motion was approved unanimously.

## **COUGH AND COLD AGENTS**

Mr. Wuest presented a brief overview of the class. PDL recommendations were discussed but not presented.

Public testimony on this class was provided on Rymed and Ed-A Hist by Jim Smith on behalf of Edwards and on Clofera and Dixel by Jackson Como, R.Ph. on behalf of Centrix.

Dr. Voulters made a motion to prefer agents that cost less than 10 dollars per prescription for the State to provide to recipients. The motion was seconded by Dr. Harper and passed unanimously by the Committee.

## **NEW AGENTS TO MARKET**

Dr. Voulters left the meeting due to a prior commitment.

Mr. Wuest presented a brief overview of each agent including its place in the market.

### **Zuplenz**

No public testimony on this class was provided.

Dr. Harper made a motion to approve the recommendations. The motion was seconded by Dr. Azomani. The motion was approved unanimously.

### **Mirepex ER**

No public testimony on this class was provided.

Dr. Azomani made a motion to approve the recommendations. The motion was seconded by Ms. Wilbanks. The motion was approved unanimously.

### **Prolia**

No public testimony on this class was provided.

Dr. Azomani made a motion to approve the recommendations. The motion was seconded by Dr. Weiland. The motion was approved unanimously.

## **Jalyn**

Public testimony on this class was provided on Jalyn by Ronald Davis, M.D. on behalf of GSK.

Dr. Weiland made a motion to approve the recommendations with the addition of Jalyn preferred. The motion was seconded by Dr. Mitchell. The motion was approved unanimously.

## **Dulera**

Public testimony on this class was provided on Dulera by Jack Putman, M.D. on behalf of Merck.

Dr. Harper made a motion to approve the recommendations with the addition of Dulera preferred. The motion was seconded by Dr. Weiland. The motion was approved unanimously.

## **Livalo**

No public testimony on this class was provided.

Dr. Brewer made a motion to approve the recommendations. The motion was seconded by Dr. Azomani. The motion was approved unanimously.

## **PDL STATUS OF AVANDIA**

Mr. Wuest provided an overview of the FDA panel's safety alert on Avandia.

Ms. Clark provided an overview on Avandia utilization.

No public testimony on this class was provided.

Dr. Mitchell made a motion to recommend that Avandia be non-preferred. The motion was seconded by Dr. Harper. The motion was approved unanimously.

## **OTHER BUSINESS**

There was no other business.

## **NEXT MEETING DATE**

Ms. Clark stated that the next P&T Committee meeting is tentatively scheduled to be March, 2011.

## **ADJOURNMENT**

There being no further business, Dr. Minor adjourned the meeting.